These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 17966175)

  • 1. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.
    Lucky AW; Maloney JM; Roberts J; Taylor S; Jones T; Ling M; Garrett S;
    J Drugs Dermatol; 2007 Oct; 6(10):981-7. PubMed ID: 17966175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.
    Draelos ZD; Carter E; Maloney JM; Elewski B; Poulin Y; Lynde C; Garrett S;
    J Am Acad Dermatol; 2007 Mar; 56(3):439.e1-10. PubMed ID: 17208334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris.
    Stotland M; Shalita AR; Kissling RF
    Am J Clin Dermatol; 2009; 10(4):221-7. PubMed ID: 19489655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable.
    Tanghetti E; Harper JC; Oefelein MG
    J Drugs Dermatol; 2012 Dec; 11(12):1417-21. PubMed ID: 23377510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial.
    Berger R; Rizer R; Barba A; Wilson D; Stewart D; Grossman R; Nighland M; Weiss J
    Clin Ther; 2007 Jun; 29(6):1086-97. PubMed ID: 17692723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris.
    Piette WW; Taylor S; Pariser D; Jarratt M; Sheth P; Wilson D
    Arch Dermatol; 2008 Dec; 144(12):1564-70. PubMed ID: 19075138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne.
    Richter JR; Förström LR; Kiistala UO; Jung EG
    J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):227-33. PubMed ID: 9883434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
    J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of the safety and efficacy of picolinic acid gel in the treatment of acne vulgaris.
    Heffernan MP; Nelson MM; Anadkat MJ
    Br J Dermatol; 2007 Mar; 156(3):548-52. PubMed ID: 17300246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapsone 7.5% Gel: A Review in Acne Vulgaris.
    Al-Salama ZT; Deeks ED
    Am J Clin Dermatol; 2017 Feb; 18(1):139-145. PubMed ID: 28005194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents.
    Raimer S; Maloney JM; Bourcier M; Wilson D; Papp K; Siegfried E; Garrett S;
    Cutis; 2008 Feb; 81(2):171-8. PubMed ID: 18441772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.
    Eichenfield LF; Lain T; Frankel EH; Jones TM; Chang-Lin JE; Berk DR; Ruan S; Kaoukhov A
    J Drugs Dermatol; 2016 Aug; 15(8):962-9. PubMed ID: 27537997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.
    Stein Gold LF; Jarratt MT; Bucko AD; Grekin SK; Berlin JM; Bukhalo M; Weiss JS; Berk DR; Chang-Lin JE; Lin V; Kaoukhov A
    J Drugs Dermatol; 2016 May; 15(5):553-61. PubMed ID: 27168264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study.
    Fleischer AB; Shalita A; Eichenfield LF; Abramovits W; Lucky A; Garrett S;
    J Drugs Dermatol; 2010 Jan; 9(1):33-40. PubMed ID: 20120423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype.
    Taylor SC; Cook-Bolden FE; McMichael A; Downie JB; Rodriguez DA; Alexis AF; Callender VD; Alvandi N
    J Drugs Dermatol; 2018 Feb; 17(2):160-167. PubMed ID: 29462223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris.
    Thiboutot DM; Willmer J; Sharata H; Halder R; Garrett S
    Clin Pharmacokinet; 2007; 46(8):697-712. PubMed ID: 17655376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the anti-inflammatory effects of topical dapsone for management of acne.
    Kircik LH
    J Drugs Dermatol; 2010 Jun; 9(6):667-71. PubMed ID: 20645528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne.
    Scheinfeld N
    Curr Opin Investig Drugs; 2009 May; 10(5):474-81. PubMed ID: 19431080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
    Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
    Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris.
    Shalita AR; Myers JA; Krochmal L; Yaroshinsky A;
    J Drugs Dermatol; 2005; 4(1):48-56. PubMed ID: 15696985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.